Search: id:"swepub:oai:lup.lub.lu.se:6b472469-ad7a-4a83-a996-3edc16040bf2" >
Skin toxicity and q...
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
-
Thaler, Josef (author)
-
Karthaus, Meinolf (author)
-
Mineur, Laurent (author)
-
show more...
-
Greil, Richard (author)
-
Letocha, Henry (author)
-
Hofheinz, Ralf (author)
-
- Fernebro, Eva (author)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Gamelin, Erick (author)
-
Banos, Ana (author)
-
Koehne, Claus-Henning (author)
-
show less...
-
(creator_code:org_t)
- 2012-09-29
- 2012
- English.
-
In: BMC Cancer. - : Springer Science and Business Media LLC. - 1471-2407. ; 12:438
- Related links:
-
https://portal.resea... (primary) (free)
-
show more...
-
http://dx.doi.org/10... (free)
-
https://bmccancer.bi...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer who have wild-type (WT) KRAS tumours. Primary efficacy and tolerability results from a phase II single-arm study of first-line panitumumab plus FOLFIRI in patients with metastatic colorectal cancer have been reported. Here we report additional descriptive tolerability and quality of life data from this trial. Methods: Integument-related toxicities and quality of life were analysed; toxicities were graded using modified National Cancer Institute Common Toxicity Criteria. Kaplan-Meier estimates of time to and duration of first integument-related toxicity were prepared. Quality of life was measured using EuroQoL EQ-5D and EORTC QLQ-C30. Best overall response was analysed by skin toxicity grade and baseline quality of life. Change in quality of life was analysed by skin toxicity severity. Results: 154 patients were enrolled (WT KRAS n = 86; mutant KRAS n = 59); most (98%) experienced integument-related toxicities (most commonly rash [42%], dry skin [40%] and acne [36%]). Median time to first integument-related toxicity was 8 days; median duration was 334 days. Overall, proportionally more patients with grade 2+ skin toxicity responded (56%) compared with those with grade 0/1 (29%). Mean overall EQ-5D health state index scores (0.81 vs. 0.78), health rating scores (72.5 vs. 71.0) and QLQ-C30 global health status scores (65.8 vs. 66.7) were comparable at baseline vs. safety follow-up (8 weeks after completion), respectively and appeared unaffected by skin toxicity severity. Conclusions: First-line panitumumab plus FOLFIRI has acceptable tolerability and appears to have little impact on quality of life, despite the high incidence of integument-related toxicity.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Colorectal cancer
- Panitumumab
- Quality of life
- Tolerability
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
-
BMC Cancer
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Thaler, Josef
-
Karthaus, Meinol ...
-
Mineur, Laurent
-
Greil, Richard
-
Letocha, Henry
-
Hofheinz, Ralf
-
show more...
-
Fernebro, Eva
-
Gamelin, Erick
-
Banos, Ana
-
Koehne, Claus-He ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
BMC Cancer
- By the university
-
Lund University